Salmonella SL7207 application is the most effective DNA vaccine delivery method for successful tumor eradication in a murine model for neuroblastoma

Cancer Letters

Volumn 331, Issue 2, 2013, Pages 167-173

  Berger, Elisa ^a   Soldati, Rocio ^a   Huebener, Nicole ^b   Hohn, Oliver ^c   Stermann, Alexander ^d   Durmus, Tahir ^e   Lobitz, Stephan ^e   Zenclussen, Ana C ^a   Christiansen, Holger ^f   Lode, Holger N ^d   Fest, Stefan ^f  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Dendritic cells; Gene gun; Lentiviral particle; Neuroblastoma; SL7207

Indexed keywords

COMPLEMENTARY DNA; DNA VACCINE; LENTIVIRUS VECTOR; PLASMID DNA; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BONE MARROW CELL; CANCER IMMUNIZATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; ERADICATION THERAPY; FEMALE; GENE DELIVERY SYSTEM; HEMATOPOIESIS; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM; WOUND HEALING;

ANIMALS; BIOLISTICS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; MICE; NEUROBLASTOMA; PLASMIDS; SALMONELLA; VACCINES, DNA;

MURINAE; SALMONELLA; SALMONELLA TYPHIMURIUM;

EID: 84875364485     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.12.026     Document Type: Article

References (50)

1. Cui Z. DNA vaccine. Adv. Genet. 2005, 54:257-289.
2. Fioretti D., Iurescia S., Fazio V.M., Rinaldi M. DNA vaccines: developing new strategies against cancer. J. Biomed. Biotechnol. 2010, 2010:174378.
3. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 2002, 20:709-760.
4. Tudor D., Dubuquoy C., Gaboriau V., Lefevre F., Charley B., Riffault S. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines. Vaccine 2005, 23:1258-1264.
5. Huebener N., Fest S., Strandsby A., Michalsky E., Preissner R., Zeng Y., Gaedicke G., Lode H.N. A rationally designed tyrosine hydroxylase DNA vaccine induces specific antineuroblastoma immunity. Mol. Cancer Ther. 2008, 7:2241-2251.
6. Rodriguez F., Zhang J., Whitton J.L. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 1997, 71:8497-8503.
7. Kloetzel P.M. Antigen processing by the proteasome. Nat. Rev. Mol. Cell Biol. 2001, 2:179-187.
8. Miller M.A., Ohashi K., Zhu X., McGrady P., London W.B., Hogarty M., Sandler A.D. Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: a report from the children's oncology group. J. Pediatr. Hematol. Oncol. 2006, 28:412-417.
9. Maris J.M., Hogarty M.D., Bagatell R., Cohn S.L. Neuroblastoma. Lancet 2007, 369:2106-2120.
10. Fest S., Huebener N., Bleeke M., Durmus T., Stermann A., Woehler A., Baykan B., Zenclussen A.C., Michalsky E., Jaeger I.S., Preissner R., Hohn O., Weixler S., Gaedicke G., Lode H.N. Survivin minigene DNA vaccination is effective against neuroblastoma. Int. J. Cancer 2009, 125:104-114.
11. Fest S., Huebener N., Weixler S., Bleeke M., Zeng Y., Strandsby A., Volkmer-Engert R., Landgraf C., Gaedicke G., Riemer A.B., Michalsky E., Jaeger I.S., Preissner R., Forster-Wald E., Jensen-Jarolim E., Lode H.N. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res. 2006, 66:10567-10575.
12. Huebener N., Fest S., Hilt K., Schramm A., Eggert A., Durmus T., Woehler A., Stermann A., Bleeke M., Baykan B., Weixler S., Gaedicke G., Lode H.N. Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma. Mol. Cancer Ther. 2009, 8:2392-2401.
13. Lu S., Wang S., Grimes-Serrano J.M. Current progress of DNA vaccine studies in humans. Expert Rev. Vaccines 2008, 7:175-191.
14. Jechlinger W. Optimization and delivery of plasmid DNA for vaccination. Expert Rev. Vaccines 2006, 5:803-825.
15. Saade F., Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev. Vaccines 2012, 11:189-209.
16. Breckpot K., Aerts J.L., Thielemans K. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. Gene Ther. 2007, 14:847-862.
17. Trimble C., Lin C.T., Hung C.F., Pai S., Juang J., He L., Gillison M., Pardoll D., Wu L., Wu T.C. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003, 21:4036-4042.
18. Darji A., Guzman C.A., Gerstel B., Wachholz P., Timmis K.N., Wehland J., Chakraborty T., Weiss S. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997, 91:765-775.
19. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
20. Xiang R., Mizutani N., Luo Y., Chiodoni C., Zhou H., Mizutani M., Ba Y., Becker J.C., Reisfeld R.A. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 2005, 65:553-561.
21. Huebener N., Lange B., Lemmel C., Rammensee H.G., Strandsby A., Wenkel J., Jikai J., Zeng Y., Gaedicke G., Lode H.N. Vaccination with minigenes encoding for novel 'self' antigens are effective in DNA-vaccination against neuroblastoma. Cancer Lett. 2003, 197:211-217.
22. Lode H.N., Huebener N., Zeng Y., Fest S., Weixler S., Gaedicke G. DNA minigene vaccination for adjuvant neuroblastoma therapy. Ann. N Y Acad. Sci. 2004, 1028:113-121.
23. Chen C.H., Ji H., Suh K.W., Choti M.A., Pardoll D.M., Wu T.C. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Gene Ther. 1999, 6:1972-1981.
24. Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Curr. Gene Ther. 2005, 5:619-628.
25. Fuller D.H., Loudon P., Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods 2006, 40:86-97.
26. Fynan E.F., Webster R.G., Fuller D.H., Haynes J.R., Santoro J.C., Robinson H.L. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA. 1993, 90:11478-11482.
27. Chang L.J. Lentiviral vector transduction of dendritic cells for novel vaccine strategies. Methods Mol. Biol. 2010, 614:161-171.
28. Li G.B., Lu G.X. A single low dose of dendritic cells modified with lentivirus containing a truncated neu gene can effectively suppress neu-overexpressing tumors. J. Gene Med. 2010, 12:604-612.
29. Lin C.T., Yen C.F., Shaw S.W., Yen T.C., Chen Y.J., Soong Y.K., Lai C.H. Gene gun administration of therapeutic HPV DNA vaccination restores the efficacy of prolonged defrosted viral based vaccine. Vaccine 2009, 27:7352-7358.
30. Sun W., Qian H., Zhang X., Zhou C., Liang X., Wang D., Fu M., Ma W., Zhang S., Lin C. Induction of protective and therapeutic antitumour immunity using a novel tumour-associated antigen-specific DNA vaccine. Immunol. Cell Biol. 2006, 84:440-447.
31. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 1999, 223:77-92.
32. Lode H.N., Xiang R., Varki N.M., Dolman C.S., Gillies S.D., Reisfeld R.A. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl. Cancer Inst. 1997, 89:1586-1594.
33. Zeng Y., Huebener N., Fest S., Weixler S., Schroeder U., Gaedicke G., Xiang R., Schramm A., Eggert A., Reisfeld R.A., Lode H.N. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. Cancer Res. 2007, 67:2331-2338.
34. Bleeke M., Fest S., Huebener N., Landgraf C., Schraven B., Gaedicke G., Volkmer R., Lode H.N. Systematic amino acid substitutions improved efficiency of GD2-peptide mimotope vaccination against neuroblastoma. Eur. J. Cancer 2009, 45:2915-2921.
35. Hegazy W.A., Hensel M. Salmonella enterica as a vaccine carrier. Future Microbiol. 2012, 7:111-127.
36. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 1994, 12:991-1045.
37. Huang B., Mao C.P., Peng S., He L., Hung C.F., Wu T.C. Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. Vaccine 2007, 25:7824-7831.
38. Idoyaga J., Steinman R.M. SnapShot: dendritic cells. Cell 2011, 146. 660-660 e662.
39. Caruso D.A., Orme L.M., Amor G.M., Neale A.M., Radcliff F.J., Downie P., Tang M.L., Ashley D.M. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer 2005, 103:1280-1291.
40. Geiger J.D., Hutchinson R.J., Hohenkirk L.F., McKenna E.A., Yanik G.A., Levine J.E., Chang A.E., Braun T.M., Mule J.J. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001, 61:8513-8519.
41. Morandi F., Chiesa S., Bocca P., Millo E., Salis A., Solari M., Pistoia V., Prigione I. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia 2006, 8:833-842.
42. Mossoba M.E., Walia J.S., Rasaiah V.I., Buxhoeveden N., Head R., Ying C., Foley J.E., Bramson J.L., Fowler D.H., Medin J.A. Tumor protection following vaccination with low doses of lentivirally transduced DCs expressing the self-antigen erbB2. Mol. Ther. 2008, 16:607-617.
43. Engels E.A., Falagas M.E., Lau J., Bennish M.L. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. BMJ 1998, 316:110-116.
44. Kirkpatrick B.D., McKenzie R., O'Neill J.P., Larsson C.J., Bourgeois A.L., Shimko J., Bentley M., Makin J., Chatfield S., Hindle Z., Fidler C., Robinson B.E., Ventrone C.H., Bansal N., Carpenter C.M., Kutzko D., Hamlet S., LaPointe C., Taylor D.N. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 2006, 24:116-123.
45. Xiong G., Husseiny M.I., Song L., Erdreich-Epstein A., Shackleford G.M., Seeger R.C., Jackel D., Hensel M., Metelitsa L.S. Novel cancer vaccine based on genes of Salmonella pathogenicity island 2. Int. J. Cancer 2010, 126:2622-2634.
46. Hindle Z., Chatfield S.N., Phillimore J., Bentley M., Johnson J., Cosgrove C.A., Ghaem-Maghami M., Sexton A., Khan M., Brennan F.R., Everest P., Wu T., Pickard D., Holden D.W., Dougan G., Griffin G.E., House D., Santangelo J.D., Khan S.A., Shea J.E., Feldman R.G., Lewis D.J. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect. Immun. 2002, 70:3457-3467.
47. Toso J.F., Gill V.J., Hwu P., Marincola F.M., Restifo N.P., Schwartzentruber D.J., Sherry R.M., Topalian S.L., Yang J.C., Stock F., Freezer L.J., Morton K.E., Seipp C., Haworth L., Mavroukakis S., White D., MacDonald S., Mao J., Sznol M., Rosenberg S.A. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J. Clin. Oncol. 2002, 20:142-152.
48. Heimann D.M., Rosenberg S.A. Continuous intravenous administration of live genetically modified salmonella typhimurium in patients with metastatic melanoma. J. Immunother. 2003, 26:179-180.
49. Reed J.C. The Survivin saga goes in vivo. J. Clin. Invest. 2001, 108:965-969.
50. Kotton C.N., Lankowski A.J., Scott N., Sisul D., Chen L.M., Raschke K., Borders G., Boaz M., Spentzou A., Galan J.E., Hohmann E.L. Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system. Vaccine 2006, 24:6216-6224.